3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Youngro Lee of Brassica, Anu Puvvada of KPMG Studio, and Brock Murphy of Parent ProTech. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from corporate innovation to fintech — recently making headlines in Houston innovation.


Youngro Lee, founder of Brassica

Youngro Lee joins the Houston Innovators Podcast to discuss his latest endeavor on his mission to democratize investing. Photo courtesy

Brassica Technologies, a fintech infrastructure company that's providing a platform for alternative assets, is just the next step in his career in using tech to democratize finance. The idea came from Lee's experience as a startup founder and fintech exec — first at NextSeed and then at Republic, which acquired NextSeed two years ago.

"The reason why I thought this was what I wanted to focus on next was exactly because it was an issue I struggled with as a founder of NextSeed," Lee says on the show. "The backend was always an issue. There's not one single vendor that we felt really understood our business, was doing it efficiently, or enabled us to deliver those services to our end clients."

Lee shares more about the future of Brassica, including the challenges he's facing within regulation and the state of fintech as a whole, on the podcast. He also weighs in on how he's seen the Houston innovation ecosystem grow and develop alongside his own entrepreneurial journey. Read more.

Anu Puvvada, KPMG Studio leader

Anu Puvvada, KPMG Studio leader, shares how her team is advancing software solutions while navigating hype cycles and solving billion-dollar-problems. Photo courtesy of KPMG

In 2021, KPMG, a New York-based global audit, accounting, and advisory service provider, formed a new entity to play in the innovation space. The Houston-based team finds innovative software that benefit KPMG's clients across industries.

In an interview with InnovationMap, Anu Puvvada, leader of KPMG Studio, shares more about the program, its first spin out, and why she's passionate about leading this initiative from Houston.

"When you think about innovation as a whole, it's mired with risk and uncertainty," she says. "You never know if something's going to work or not. And part of what we have to do with any idea that we're building in the studio or anything that our clients are doing around innovation, we have to do as much as we can to mitigate that risk and uncertainty. And that's kind of what KPMG's wheelhouse is." Read more.

Brock Murphy, Parent ProTech co-founder

Brock Murphy launched Parent ProTech last fall. Photo via parentprotech.com

Houston-based Parent ProTech is a one-stop shop for parental education on technology and applications that their kids use.

“Our goal is to make everyone the best digital parent possible,” Brock Murphy, Parent ProTech co-founder, tells InnovationMap. “We understand technology and the role it plays in influencing the next generation. So we help parents when it comes to understanding the platforms, how to use them and how to unlock the parental controls that can be hidden, deeper into these platforms.”

Murphy — with co-founder Drew Wooten and creative director Joshua Adams — launched the platform in September 2022. Since then, Parent ProTech has made its mark through partnerships with schools in Texas. Read more.

Anu Puvvada, KPMG Studio leader, shares how her team is advancing software solutions while navigating hype cycles and solving billion-dollar-problems. Photo courtesy of KPMG

How this Houston-based studio is tackling billion-dollar problems with internal innovation

Q&A

In 2021, KPMG, a New York-based global audit, accounting, and advisory service provider, formed a new entity to play in the innovation space. The Houston-based team finds innovative software that benefit KPMG's clients across industries.

"We're really focused on transformative businesses that we can offer our clients in the next three to five years to solve fairly large problems," Anu Puvvada, KPMG Studio leader, tells InnovationMap.

Now, almost two years later, KPMG Studio has spun out its first company, AI-based security startup Cranium, which has raised $7 million in a seed round led by SYN Ventures with support from KPMG.

Established to advance internal innovation, KPMG Studio's technologies don't always get spun out into startups like Cranium, but with support of the team, the early-stage ideas receive guidance from the company's resources with the potential to be rolled into KPMG's suite of services for its clients.

In an interview with InnovationMap, Puvvada shares more about the program, the Cranium spin out, and why she's passionate about leading this initiative from Houston.

InnovationMap: Tell me about KPMG Studio's structure and your overall goal with the program.

Anu Puvvada: I like to think about it more around framing. We frame the studio around three pillars: incubate, accelerate and amplify. We take in a lot of ideas that come from the business and from our clients and we incubate and see which of them are really high growth solving like a very large problem across verticals and horizontals. When I say a big problem — it's got to be a $1 billion-plus problem. With Cranium, we saw some very early indicators, like a rise in AI adoption amongst our clients. We saw that AI was in this spot where it was going to hit an exponential growth marker. We also saw a rise in cyber attacks. All of that plus conversations with clients made us realize that there's there's something big brewing here.

We're looking at a ton of ideas, and then parsing out maybe 10 that we create into the next Cranium. And then in accelerate, we're finding early adopters and we're growing the idea, building it, raising venture capital for the idea if we decide to spin it out.

IM: Seems like a mutually beneficial relationship between KPMG and these innovators, right?

AP: I would say it's good for KPMG because it allows us to innovate differently and innovate with agility. My group actually operates as a startup within a large organization. And then we create this ecosystem around startups inside KPMG, so when it exits, it's got the basis to run on its own. That's important for us because it gives us agility, it lets us really capitalize on our brand. It's not just what it brings us, but also what it brings our clients.

There's a big competitive advantage to innovating inside KPMG. These innovators get to work inside our walls protected by the infrastructure of KPMG. They, they get a technology team to help them build the idea. And they get to use their brand of KPMG, use our marketing engine, our comms engine, like everything that's behind us. A startup outside, it doesn't get any of that. So, it almost like accelerates them into market when the spin out happens. We use the differentiators and the competitive advantage of KPMG in order to amplify the story of that startup and their value proposition in the market.

IM: So there are two paths for these technologies, right?

AP: We either have what we call spin ins, which means it's created and spins into the business or we have spin outs, which is what Cranium is. We classify spin outs into its own startup or a sale of an asset. And then for the spin in, we would license to our clients under the mothership of KPMG.

IM: Is the studio operating completely in Houston?

AP: We source our ideas from all over nationally. I'm in Houston and a lot of my support team is actually in Houston as well. And I work with a lot of the Houston ecosystem around innovation. I really see Houston as a big future market. We are at the center of climate and ESG, the space economy, and medicine. Those are three big like curves that are going to be hitting in the next five years. So, it is integral for studio to be integrated into that ecosystem to position KPMG for the future.

IM: What's your vision for the studio?

AP: I definitely see us taking in more ideas into studio to build internally for our pioneers, which is what we call our innovators — Jonathan Dambrot, who is the founder of Cranium, he's the pioneer. We'll definitely be doing more Craniums that spin out of the firm. And we have a number that are spinning into the firm already.

I also see us evolving to bring in external startups into the studio so we can also give them the entire ecosystem a way to be lifted up and to shepherd each other into the future.

It's really important that anything that we invest in and we work on is staying measured through these hype cycles that are happening. We need to make sure that these ideas are grounded in the problem that's being solved in an adaptable way and that there's a strong market need for it. That's something that the studio really spends a lot of time doing in the beginning, which kind of helps mitigate some of these hype cycles for us and our clients.

When you think about innovation as a whole, it's mired with risk and uncertainty. You never know if something's going to work or not. And part of what we have to do with any idea that we're building in the studio or anything that our clients are doing around innovation, we have to do as much as we can to mitigate that risk and uncertainty. And that's kind of what KPMG's wheelhouse is.

------

This conversation has been edited for brevity and clarity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

5 must-read innovation headlines: Pharma giant considers Houston hub + more

Trending news

Editor's note: With May coming to a close, it's time to look back at the biggest innovation headlines for the second half of the month. Major moves were made in May, with NuScale Power entering the market, Persona AI inking a deal with Under Armour, and a pharma giant considering Houston for its next manufacturing hub. Here are the most-read InnovationMap stories published May 15-29, 2026:

1. Pharma giant considers Houston for $1 billion manufacturing campus

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub. According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

2. Modular nuclear reactor co. NuScale Power moves into Houston market

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

3. Persona AI teams with Under Armour to protect next-gen robots

Houston-based Persona AI has cemented a partnership with sportswear manufacturer Under Armour to provide materials to protect future robots operating in dangerous conditions. Through the partnership, Persona AI and Under Armour will launch a research initiative to explore whether advanced performance textiles can improve the durability and resilience of humanoid robots operating in harsh industrial environments.

4. Houston quantum energy chip startup emerges from stealth with $12M round

Houston-based Casimir has emerged from stealth with a $12 million seed round to commercialize its quantum energy chip. The round was led by Austin-based Scout Ventures. Lavrock Ventures, Cottonwood Technology, Capital Factory, American Deep Tech, and Tim Draper of Draper Associates also participated in the round. The oversubscribed round exceeded the company’s original $8 million target.

5. Global summit spotlights Houston's growing role in brain health, innovation

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. The summit, held June 9-10 at the Texas Medical Center's Helix Park, will bring together more than 500 executives, researchers, policymakers and innovators from around the world to discuss the global brain economy.

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

View All Listings